Arde­lyx scraps PhI­II drug af­ter re­searchers raise a safe­ty is­sue for hy­per­kalemia pa­tients

The roller coast­er ride at Arde­lyx is con­tin­u­ing to­day with news that one of their late-stage as­sets is be­ing scrapped.

With their lead drug tena­panor be­ing slow­ly guid­ed to reg­u­la­tors and a hoped-for mar­ket show­down for ir­ri­ta­ble bow­el syn­drome, Arde­lyx $ARDX re­port­ed that it has de­cid­ed to scut­tle its Phase III pro­gram for RDX7675 in pa­tients with hy­per­kalemia af­ter track­ing a safe­ty is­sue — drug-re­lat­ed re­duc­tion in serum bi­car­bon­ate, which can trig­ger a de­ci­sion to stop treat­ment — which es­sen­tial­ly blew up its plans to mar­ket this treat­ment for chron­ic cas­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER